Literature DB >> 26097154

Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.

Erin L Karschner1,2, Madeleine J Swortwood1, Jussi Hirvonen3,4, Robert S Goodwin1,5, Wendy M Bosker1,6,7, Johannes G Ramaekers7, Marilyn A Huestis1.   

Abstract

Cannabis smoking increases motor vehicle accident risk. Empirically defined cannabinoid detection windows are important to drugged driving legislation. Our aims were to establish plasma cannabinoid detection windows in frequent cannabis smokers and to determine if residual cannabinoid concentrations were correlated with psychomotor performance. Twenty-eight male chronic frequent cannabis smokers resided on a secure research unit for up to 33 days with daily blood collection. Plasma specimens were analyzed for Δ(9) -tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) by gas chromatography-mass spectrometry. Critical tracking and divided attention tasks were administered at baseline (after overnight stay to ensure lack of acute intoxication) and after 1, 2, and 3 weeks of cannabis abstinence. Twenty-seven of the twenty-eight participants were THC-positive at admission (median 4.2 µg/L). THC concentrations significantly decreased 24 h after admission, but were still ≥2 µg/L in 16 of the 28 participants 48 h after admission. THC was detected in 3 of 5 specimens on day 30. The last positive 11-OH-THC specimen was 15 days after admission. THCCOOH was measureable in 4 of 5 participants after 30 days of abstinence. Years of prior cannabis use significantly correlated with THC concentrations on admission, and days 7 and 14. Tracking error, evaluated by the Divided Attention Task, was the only evaluated psychomotor assessment significantly correlated with cannabinoid concentrations at baseline and day 8 (11-OH-THC only). Median THC was 0.3 µg/L in 5 chronic frequent cannabis smokers' plasma samples after 30 days of sustained abstinence. Published 2015. This article is a U.S. Government work and is in the public domain in the USA. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  abstinence; cannabinoid; cannabis; chronic; Δ9-tetrahydrocannabinol

Mesh:

Substances:

Year:  2015        PMID: 26097154      PMCID: PMC4676741          DOI: 10.1002/dta.1825

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  45 in total

1.  Neuropsychological performance in long-term cannabis users.

Authors:  H G Pope; A J Gruber; J I Hudson; M A Huestis; D Yurgelun-Todd
Journal:  Arch Gen Psychiatry       Date:  2001-10

2.  THC can be detected in brain while absent in blood.

Authors:  Patrick Mura; Pascal Kintz; Véronique Dumestre; Sébastien Raul; Thierry Hauet
Journal:  J Anal Toxicol       Date:  2005 Nov-Dec       Impact factor: 3.367

3.  Pharmacokinetics and disposition of delta 9-tetrahydrocannabinol and its metabolites.

Authors:  E R Garrett
Journal:  Adv Biosci       Date:  1978 Jul 22-23

Review 4.  Cannabis effects on driving skills.

Authors:  Rebecca L Hartman; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-12-07       Impact factor: 8.327

5.  Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

6.  Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.

Authors:  Eugene W Schwilke; Erin L Karschner; Ross H Lowe; Ann M Gordon; Jean Lud Cadet; Ronald I Herning; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

7.  Prolonged apparent half-life of delta 1-tetrahydrocannabinol in plasma of chronic marijuana users.

Authors:  E Johansson; S Agurell; L E Hollister; M M Halldin
Journal:  J Pharm Pharmacol       Date:  1988-05       Impact factor: 3.765

8.  Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Harrison G Pope; Ronald Herning; Jean L Cadet; Marilyn A Huestis
Journal:  Addiction       Date:  2009-10-05       Impact factor: 6.526

9.  Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite.

Authors:  P L Williams; A C Moffat
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

10.  Psychomotor function in chronic daily Cannabis smokers during sustained abstinence.

Authors:  Wendy M Bosker; Erin L Karschner; Dayong Lee; Robert S Goodwin; Jussi Hirvonen; Robert B Innis; Eef L Theunissen; Kim P C Kuypers; Marilyn A Huestis; Johannes G Ramaekers
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

View more
  5 in total

1.  8β-OH-THC and 8β,11-diOH-THC-minor metabolites with major informative value?

Authors:  Angela Gasse; Heidi Pfeiffer; Helga Köhler; Jennifer Schürenkamp
Journal:  Int J Legal Med       Date:  2017-10-05       Impact factor: 2.686

2.  Effects of High-Potency Cannabis on Psychomotor Performance in Frequent Cannabis Users.

Authors:  Hollis C Karoly; Michael A Milburn; Ashley Brooks-Russell; Mary Brown; Jessica Streufert; Angela D Bryan; Nicholas P Lovrich; William DeJong; L Cinnamon Bidwell
Journal:  Cannabis Cannabinoid Res       Date:  2020-09-10

3.  Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study.

Authors:  Jeffrey R Brubacher; Herbert Chan; Shannon Erdelyi; Scott Macdonald; Mark Asbridge; Robert E Mann; Jeffrey Eppler; Adam Lund; Andrew MacPherson; Walter Martz; William E Schreiber; Rollin Brant; Roy A Purssell
Journal:  Addiction       Date:  2019-07-03       Impact factor: 6.526

4.  Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?

Authors:  Benedikt Bernd Claus; Michael Specka; Heath McAnally; Norbert Scherbaum; Fabrizio Schifano; Udo Bonnet
Journal:  Front Psychiatry       Date:  2020-12-03       Impact factor: 4.157

5.  A comprehensive breath test that confirms recent use of inhaled cannabis within the impairment window.

Authors:  Michael W DeGregorio; Gregory T Wurz; Edward Montoya; Chiao-Jung Kao
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.